Hepatitis B vaccine in Saudi children
Bahrain Medical Bulletin. 1992; 14 (3): 86-7
em Inglês
| IMEMR
| ID: emr-23197
ABSTRACT
The aim of our study is to know the protective efficacy and immunogenicity of Engerix B [Recombinant Deoxyribonucleic acid-Yeast derived Hepatitis B vaccine]. In 1987, 113 seronegative children were vaccinated intramuscularly in the quadriceps region with 1.0 ml of Engerix B. Serum samples were collected at month 1, 2, 7, 12 and tested for Anti HBs levels. The seroconversion rates for HBs Antibodies were 28% at month 1.79% at month 2.94% at month 7 and 92% at month 12. No significant adverse reactions were noticed
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Vacinas Sintéticas
Limite:
Humanos
Idioma:
Inglês
Revista:
Bahrain Med. Bull.
Ano de publicação:
1992
Similares
MEDLINE
...
LILACS
LIS